International Journal of Pathology Sciences

ISSN Print: 2664-9063
ISSN Online: 2664-9071
IJPS 2024; 6(1): 36-38
www.pathologyjournal.net
Received: 06-07-2024
Accepted: 13-08-2024

Dr. Abdelhakim Zahra Lahlou
Department of Rheumatology, Mohammed V University, Rabat, Morocco

Corresponding Author:
Dr. Abdelhakim Zahra Lahlou
Department of Rheumatology, Mohammed V University, Rabat, Morocco

Immunopathological findings in rheumatoid arthritis: A comprehensive review

Dr. Abdelhakim Zahra Lahlou

DOI: https://doi.org/10.33545/26649063.2024.v6.i1a.20

Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, leading to joint destruction and systemic manifestations. The immunopathological mechanisms underlying RA are complex, involving a dysregulated immune response that targets self-antigens in the synovial tissue. This review provides a detailed examination of the immunopathological findings in RA, focusing on the roles of various immune cells, cytokines, autoantibodies, and genetic factors. The review also explores recent advancements in understanding the molecular pathways involved in RA pathogenesis, highlighting potential therapeutic targets and the implications for personalized medicine.

Keywords: Rheumatoid arthritis, dysregulated immune, personalized medicine

Introduction
Rheumatoid arthritis (RA) is a debilitating autoimmune disease that affects approximately 1% of the global population. It is characterized by chronic inflammation of the synovial joints, leading to pain, swelling, and eventual destruction of cartilage and bone. Despite extensive research, the exact cause of RA remains elusive, although it is widely recognized that the disease arises from a combination of genetic predisposition and environmental triggers, which lead to an aberrant immune response.
The immunopathology of RA is driven by a complex interplay between innate and adaptive immune mechanisms. Central to this process is the loss of immune tolerance, where the body's immune system erroneously recognizes self-antigens as foreign and mounts an immune response against them. This immune dysregulation involves multiple cellular and molecular components, including T cells, B cells, macrophages, dendritic cells, and a variety of pro-inflammatory cytokines and chemokines.

Objective of paper
The objective of this paper is to comprehensively review the immunopathological mechanisms underlying rheumatoid arthritis (RA), focusing on the roles of various immune cells, cytokines, autoantibodies, and genetic factors in the disease's pathogenesis.

Immune Cells Involved in RA
T Cells: T cells, particularly CD4+ T helper cells, play a pivotal role in the pathogenesis of RA. Th1 and Th17 cells are the predominant T cell subsets involved in the disease. Th1 cells produce interferon-gamma (IFN-γ), a cytokine that activates macrophages and promotes inflammation. Th17 cells secrete interleukin-17 (IL-17), which further amplifies the inflammatory response by recruiting neutrophils and enhancing the production of other pro-inflammatory cytokines such as IL-6 and tumor necrosis factor-alpha (TNF-α). Studies have shown that the synovial fluid of RA patients contains elevated levels of IL-17, correlating with disease severity and joint damage.

B Cells: B cells contribute to RA pathogenesis through the production of autoantibodies, antigen presentation, and cytokine secretion. The presence of autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) is a hallmark of RA and is associated with more severe disease. ACPAs target citrullinated peptides, which are modified forms of proteins that occur during inflammation. The formation of immune complexes containing these autoantibodies can deposit in the joints, leading to complement activation and further inflammation.

Macrophages and Dendritic Cells

Macrophages are abundant in the synovial tissue of RA patients and are a major source of pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6. These cytokines not only sustain the inflammatory environment but also contribute to the systemic manifestations of RA, such as fatigue, anemia, and cardiovascular disease. Dendritic cells (DCs), as professional antigen-presenting cells, play a crucial role in initiating and maintaining the autoimmune response in RA by presenting autoantigens to T cells and producing inflammatory cytokines.

Cytokines and chemokines

TNF-α and IL-6

TNF-α is one of the key cytokines involved in RA and plays a central role in driving the inflammatory cascade. TNF-α promotes the activation of endothelial cells, leading to increased vascular permeability and leukocyte infiltration into the synovial tissue. IL-6 is another critical cytokine that mediates the acute phase response and stimulates the production of C-reactive protein (CRP), a marker of inflammation in RA. Both TNF-α and IL-6 have been successfully targeted in RA therapy, with TNF inhibitors and IL-6 receptor blockers showing significant efficacy in reducing disease activity and preventing joint damage.

IL-17

IL-17, predominantly produced by Th17 cells, has emerged as a key cytokine in RA pathogenesis. IL-17 stimulates fibroblasts, chondrocytes, and osteoblasts to produce matrix metalloproteinases (MMPs) and other enzymes that degrade cartilage and bone. The involvement of IL-17 in RA has led to the development of IL-17 inhibitors as a therapeutic option for patients who do not respond adequately to traditional therapies.

Chemokines

Chemokines such as CCL2 (MCP-1), CXCL8 (IL-8), and CXCL10 (IP-10) are critical for the recruitment of immune cells to the inflamed synovium. These chemokines attract monocytes, neutrophils, and T cells to the site of inflammation, perpetuating the inflammatory response. Elevated levels of these chemokines in the synovial fluid and serum of RA patients have been correlated with disease activity and joint damage.

Autoantibodies

Rheumatoid Factor (RF) and ACPAs

Rheumatoid factor (RF) is an autoantibody that targets the Fc portion of IgG, forming immune complexes that contribute to inflammation. RF is found in approximately 70-80% of RA patients and is associated with more severe disease and extra-articular manifestations. Anti-citrullinated protein antibodies (ACPAs) are more specific for RA and can be detected years before the onset of clinical symptoms. ACPAs recognize citrullinated epitopes generated by the post-translational modification of arginine residues to citrulline, a process that occurs in the inflammatory environment of the synovium.

Other Autoantibodies

In addition to RF and ACPAs, other autoantibodies have been identified in RA, including anti-carbamylated protein (anti-CarP) antibodies and anti-peptidylarginine deiminase (anti-PAD) antibodies. These autoantibodies are associated with disease progression and severity, highlighting the complex autoimmune nature of RA.

Genetic Factors

HLA-DRB1 and the Shared Epitope

Genetic predisposition plays a significant role in the development of RA, with the HLA-DRB1 gene being the most strongly associated genetic factor. The shared epitope, a specific sequence of amino acids in the HLA-DRB1 molecule, is present in several HLA-DRB1 alleles and is associated with an increased risk of developing RA. The shared epitope hypothesis suggests that this sequence may influence the binding and presentation of citrullinated peptides to T cells, thereby promoting the autoimmune response.

Non-HLA Genes

In addition to HLA-DRB1, several non-HLA genes have been implicated in RA susceptibility, including PTPN22, STAT4, and PADI4. These genes are involved in immune regulation and cytokine signaling, contributing to the dysregulated immune response observed in RA. Genome-wide association studies (GWAS) have identified numerous loci associated with RA, providing insights into the genetic architecture of the disease and potential therapeutic targets.

Molecular pathways and therapeutic implications

NF-κB and JAK-STAT Pathways

The NF-κB and JAK-STAT signaling pathways are central to the inflammatory response in RA. NF-κB is a transcription factor that regulates the expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Aberrant activation of NF-κB in synovial cells and immune cells contributes to chronic inflammation and joint destruction. The JAK-STAT pathway is activated by cytokines such as IL-6 and IFN-γ, leading to the transcription of genes involved in inflammation and immune regulation. Targeting these pathways with specific inhibitors, such as JAK inhibitors, has shown promise in reducing inflammation and improving clinical outcomes in RA patients.

Therapeutic Targets

The identification of key molecules and pathways involved in RA has led to the development of targeted therapies, including TNF inhibitors, IL-6 receptor antagonists, IL-17 inhibitors, and JAK inhibitors. These biologic agents have revolutionized the treatment of RA, offering more effective and personalized treatment options for patients. Ongoing research is focused on identifying novel targets and developing new therapies that can modulate the immune

response more precisely, with the goal of achieving remission and preventing disease progression.

Conclusion

Rheumatoid arthritis is a complex autoimmune disease characterized by a dysregulated immune response that targets synovial tissue, leading to chronic inflammation and joint destruction. The immunopathological findings in RA highlight the roles of various immune cells, cytokines, autoantibodies, and genetic factors in the pathogenesis of the disease. Advances in our understanding of these mechanisms have led to the development of targeted therapies that have significantly improved patient outcomes. However, challenges remain in achieving sustained remission and preventing long-term complications. Future research is needed to further elucidate the molecular pathways involved in RA and to develop more effective and personalized treatment strategies.

References

1. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46(2):183-196.
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
4. Catrina AI, Svensson CI, Malmström V, Schett G, Klareskog L. Mechanisms leading from autoimmunity to arthritis. Curr Opin Immunol. 2017;49:151-158.
5. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.
6. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344(12):907-916.
7. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Rev Immunol. 2003;3(6):502-512.
8. Raptopoulou A, Sidiropoulos P, Katsouraki M, Boumpas DT. Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts. Crit Rev Clin Lab Sci. 2007;44(4):339-363.
9. Burska AN, Sakthiswary R, Sattar N. Rheumatoid arthritis and cardiovascular disease: an update. J Int Med Res. 2014;42(6):1257-1271.
10. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537-3545.
11. Deane KD, Demoruelle MK, Kelmenson LB, *et al*. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017;31(1):3-18.
12. Smolen JS, Landewe R, Bijlsma J, *et al*. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-977.
13. Taylor PC, Keystone EC, van der Heijde D, *et al*. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652-662.
14. Klareskog L, Padyukov L, Rönnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr. Opin. Immunol. 2006;18(6):650-655.